Chi Meng Fong
Stock Analyst at Bank of America Securities
(1.80)
# 3,372
Out of 5,040 analysts
44
Total ratings
40%
Success rate
0.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chi Meng Fong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Reiterated: Hold | $38 → $41 | $34.21 | +19.85% | 28 | Sep 22, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $21 → $25 | $17.41 | +43.60% | 5 | Aug 7, 2026 | |
| SUPN Supernus Pharmaceuticals | Reiterated: Buy | $63 | $42.14 | +49.50% | 1 | Jul 13, 2026 | |
| CCCC C4 Therapeutics | Rated: Hold | n/a | $2.85 | n/a | 5 | Oct 31, 2023 | |
| FHTX Foghorn Therapeutics | Rated: Hold | n/a | $1.99 | n/a | 5 | Oct 6, 2023 |
Roivant Sciences
Sep 22, 2026
Reiterated: Hold
Price Target: $38 → $41
Current: $34.21
Upside: +19.85%
Relay Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $21 → $25
Current: $17.41
Upside: +43.60%
Supernus Pharmaceuticals
Jul 13, 2026
Reiterated: Buy
Price Target: $63
Current: $42.14
Upside: +49.50%
C4 Therapeutics
Oct 31, 2023
Rated: Hold
Price Target: n/a
Current: $2.85
Upside: n/a
Foghorn Therapeutics
Oct 6, 2023
Rated: Hold
Price Target: n/a
Current: $1.99
Upside: n/a